(March 10, 2024)

March 22, Friday

17:00 - 18:30
Registration and Reception
18:30 - 20:30
Business Meeting (closed meeting)


March 23, Saturday, 8:30 - 21:00

8:30 - 8:40
Opening Address (Toshihiko Torigoe, President of JACI)
8:40 - 9:10
Keynote Lecture

Chairman: Dr. Toshihiko Torigoe (Sapporo Medical University)

Designing precision combination cancer immunotherapy targeting essential immune regulation points
Dr. Yutaka Kawakami (International University of Health and Welfare)

9:10 - 9:50
Spatial Biology of Tertiary Lymphoid Structure

Chairman: Dr. Yutaka Kawakami (International University of Health and Welfare)

Online lecture: Dendritic cells form and maintain tertiary lymphoid structures (TLSs) in cancer contributing to immunotherapeutic responses.
Drs. Raphael Mattiuz and Miriam Merad (Icahn School of Medicine at Mount Sinai, USA)

10:00 - 11:30
Clinical Immuno-Oncology : Combination Therapy and Biomarkers

Chairmen: Drs. Yuki Kagoya (Keio University) and Yosuke Togashi (Okayama University)


Video Lecture: Immunotherapy biomarkers for metastatic triple negative breast cancer
Dr. Leisha A. Emens (President of SITC, ANKYRA Therapeutics, USA)


Understanding the mechanisms of resistance to CAR-T cell therapy at the molecular level
Dr. Yuki Kagoya (Keio University)


Differences in PD-1 occupancy on target immune cells affect efficacy
Dr. Kiyoshi Yoshimura (Showa University)

11:45 - 12:45
Lunchon Seminar on Cancer Immuno-Pathology sponsored by MDPI and Toppan Inc.(日本語講演)

Chairman: Dr. Naoko Ohtani (Osaka Metropolitan University)

Perspectives of histopathological analysis in cancer immunotherapy.(in Japanese)
Drs. Yoshihiko Hirohashi (Sapporo Medical University) and Rii Morimura (Toppan Holdings Inc.)

13:00 - 15:10
Dissecting the Tumor Microenvironment

Chairmen: Drs. Wouter Scheper (Netherlands Cancer Institute) and Hiroyoshi Nishikawa (National Cancer Center)


Contribution of tumor endothelial cells in tumor progression
Dr. Kyoko Hida (Hokkaido University)


Cancer-specific T cell features in the tumor microenvironment
Dr. Yosuke Togashi (Okayama University)


Immune-genome analysis of immunosuppressive mechanisms in the tumor microenvironment
Dr. Hiroyoshi Nishikawa (National Cancer Center Japan, Nagoya University)


Functional decoding of intratumoral T cell repertoires through genetic screen
Dr. Wouter Scheper (Netherlands Cancer Institute, The Netherlands)

New Modalities of Cancer Immunotherapy

Chairmen: Drs. Hiroaki Ikeda (Nagasaki University) and Tomohide Tsukahara (Sapporo Medical University)


Video Lecture: Therapeutic targeting of intratumoral myeloid cells
Dr. Thomas Marron (Icahn School of Medicine at Mount Sinai, USA)


Development of cancer immunotherapy that overcomes tumor heterogeneity.
Dr. Hiroaki Ikeda (Nagasaki University)


Cell therapy using CCL19-expressing syngeneic or allogeneic mesenchymal stromal cells
Drs. Yuichi Iida and Mamoru Harada (Shimane University)

17:00 - 17:50
Special Lecture

Chairman: Dr. Toshihiko Torigoe (Sapporo Medical University)

To be or not to be: That is the question of cancer immunology
Dr. Erwei Song (Sun Yat-Sen University, Guangzhou, China)

18:00 - 19:30
Poster Discussion with free drinks
19:30 - 21:00
Social Gathering and Meet the Experts

Dr. Leisha A. Emens: Video introduction of SITC
Dr. Erwei Song: Introduction of Sun Yat-Sen University
Dr. Wouter Scheper: Introduction of Netherlands Cancer Institute


March 24, Sunday, 8:30 - 12:40

8:30 - 9:40
Neoantigens and Cancer Vaccines

Chairman: Dr. Shinichiro Fujii (RIKEN)


Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes and characterization of neoantigen-reactive CD4+ T cell
Drs. Takayuki Kanaseki and Toshihiko Torigoe (Sapporo Medical University)


Online lecture:Interrogation of tumor-specific T Cells towards improving cancer immunotherapy
Dr. Matthew M. Gubin (MD Anderson Cancer Center, USA)

Bioengineering for Cancer Immunotherapy

Chairman: Dr. Takayuki Kanaseki (Sapporo Medical University)


Online lecture:Spatiotemporally programming cytokine immunotherapy for cancer
Dr. Karl Dane WittrupWittrup (Massachusetts Institute of Technology, USA)


Harnessing stem-like memory NK and CD8+ T cells elicited by therapeutic vaccine, artificial adjuvant vector cells (aAVC) together with CD122-biased IL-2/anti-IL-2 Ab complex
Dr. Shinichiro Fuj(RIKEN)

11:00 - 12:40
Senescence, Metabolism, and Stress Responses in Cancer Immunity

Chairmen: Drs. Thales Papagiannakopoulos (New York University) and Hozumi Motohashi (Tohoku University)


The role of senescence-associated secretory phenotype (SASP) in modulating anti-tumor immunity in steatosis-associated liver cancer
Dr. Naoko Ohtani (Osaka Metropolitan University)


Supersulfides are key molecules for immune suppression in NRF2-activated cancer
Drs. Madoka Kawaguchi and Hozumi Motohashi (Tohoku University)


Dissecting the crosstalk of nutrient sensing, stress response signaling and immune evasion
Dr. Thales Papagiannakopoulos (New York University, USA)

12:40 - 12:45
Closing Remarks


Poster Session (March 23, Sat. 18:00 – 19:30)

No. 01

Identification of naturally presented oncogenic KRAS neoepitope species by mass spectrometry
Yuriko Minegishi (Japanese Foundation for Cancer Research, Japan)

No. 02

Detection of KRAS G12D G12V-derived neoepitopes from mutant KRAS cell lines using Mikros-LCMS
Noriko Iwamoto (Shimadzu Corporation, Technology Research Laboratory, Japan)

No. 03

Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes
Serina Tokita (Sapporo Medical University, Japan)

No. 04

TCR-T therapy combined with ferroptosis inducer overcomes tumor heterogeneity that consists of escape variants.
Daisuke Ehara (Nagasaki university, Japan)

No. 05

Development of T cell receptor gene-transferred T (TCR-T) cell therapy targeting carcinoembryonic antigen glypican-3
Kazunobu Ohnuki (EPOC, National Cancer Center, Japan)

No. 06

Establishment of a NK cell line to evaluate cytotoxicity of cloned TCRs
Eiji Kobayashi (University of Toyama, Japan)

No. 07

Development of allogeneic CAR-T cells with reduced immunogenicity
Chisato Umehara (Keio University, Japan)

No. 08

Application of EPHB4 targeting chimeric antigen receptor T cell (CAR-T) therapy for oral squamous cell carcinoma
Masaya Kinjo (Exploratory Oncology Research & Clinical Trial Center, National Cancer Center,Japan)

No. 09

Cancer cell derived blood EVs are potential predictive biomarkers for NSCLC patients treated with anti-PD-1 antibody
Shigeki Ohta (International University of Health and Welfare, Japan)

No. 10

refmAb-Q nSMOL, a multiplexed and universal LC-MS/MS assay platform for therapeutic antibody quantitation
Takashi Shimada (Technology Research Laboratory, Shimadzu Corporation, Japan)

No. 11

Tumor antigen-reactive CD8+ T cell population in tumor-infiltrating lymphocytes associate with better prognosis in gastric cancer
Nobuo Tsukamoto (Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan)

No. 12

Alternation of anti-tumor responses and PD-L1 blockade effects in the squamous cell carcinoma cell-inoculated aged mouse model
Chenyang Zhang (Tokyo Medical and Dental University (TMDU), Japan)

No. 13

Tumor-promoting interactome/network analysis during ther progression of MASLD/MASH-associated liver cancer model
Yoshiki Nonaka (Osaka Metropolitan University, Japan)

No. 14

A latent role of Sipa1 deficient mesenchymal stroma cells revealed in tumor resistant.
Kentaro Sumida (Medical Innovation Center, Graduate School of Medicine, Kyoto University,Japan)

No. 15

Identification of the origin of Amomi semen species with NK cell immunomodulatory activities
Yoshimasa Yamamoto (University of Toyama, Japan)

No. 16

Investigation the association between tumor cells and macrophages by the tissue section-based transcriptomics analysis for metastatic lung tissue of MMTV-PyMT mice
Tadashi Imafuku (Wakayama Medical University, Japan)

No. 17

Development of 3D stromal tissue model for in vitro evaluating the behavior of immune cells.
Rii Morimura (TOPPAN Holdings Inc., Japan)

No. 18

CD8 TILs acquire tissue-resident memory characteristics within distinct tumor microenvironment
Kosuke Kitahata (RIKEN Center for Investigative Medical Science, Japan)

No. 19

Personal immune profiles of oral tongue squamous cell carcinoma -Part 1: Analyses of 87 cases of surgical specimens and immune subtype classification-
Yuya Su (Tokyo Medical and Dental University, Japan)

No. 20

Personal immune profiles -Part 2: Analyses of the patients treated with PD-1 immune checkpoint inhibitors-
Ryo Ouchi (Tokyo Medical and Dental University and Toyama University, Japan)

No. 21

Impact of surgery on outcome under systemic therapy in advance hepatocellular carcinoma
Shinji Itoh (Kyushu University, Japan)